Kraft Heinz and Uber Eats Team Up to Launch HEINZ Verified: A New Program That Shows Consumers Which Restaurants Serve HEINZ
PITTSBURGH & CHICAGO--(BUSINESS WIRE)--Eighty-four percent of people say they would like a restaurant more if it served HEINZ Ketchup. 1 To address this desire, today, The Kraft Heinz Company (Nasdaq: KHC) ('Kraft Heinz' or the 'Company') announced the launch of HEINZ Verified, a program designed to single out restaurants that serve HEINZ, signaling a commitment to quality and excellence. HEINZ Verified is the latest program from the Company's Away From Home business, which is a key growth pillar for Kraft Heinz.
In today's landscape, it is harder than ever for restaurants to succeed, and Kraft Heinz aims to help enable their success. The Company is collaborating with Uber Eats as its inaugural platform partner for the program, and people in Chicago, Dallas, Denver, Los Angeles, Miami, and Pittsburgh can now find HEINZ Verified restaurants on the Uber Eats app. For a limited time, users can also enjoy $5 off Uber Eats orders of $30 or more when ordered from HEINZ Verified restaurants (Taxes and fees apply. See Uber Eats app for details). Kraft Heinz will provide restaurants that are HEINZ Verified with access to insights and consumer trends, free product samples, promotions, branded merchandise, digital resources and free marketing support designed to drive customer traffic.
"By introducing HEINZ Verified, we want to help restaurants succeed so communities can thrive – delivering quality and value for both restaurants and individuals through meaningful, best-in-class products and experiences,' said Peter Hall, President of Elevation, North America at Kraft Heinz. "Our ambition is to help restaurant operators excel while also providing elevated dining experiences for people wherever they eat away from home.'
HEINZ Verified is the latest program underscoring HEINZ's longstanding commitment to delivering unparalleled quality for its fans. For over 150 years, Kraft Heinz's largest brand has gone all-in to ensure its unmistakable taste is delivered every time. The global brand celebrates and prides itself on the irrational love it inspires – from real fans' personal love affairs with the brand to the undeniable love and care its products are made with. And it's clear fans recognize the brand's commitment to excellence, with a majority agreeing that when eating out, it has to be HEINZ. 1
'This exciting new partnership with HEINZ spotlights restaurants on the Uber Eats platform across the country serving the products people know and crave,' said Alex DiValerio, Head of Restaurant Operations, North America at Uber. 'This collaboration makes it easier than ever for consumers to discover local favorites featuring HEINZ products – and helps drive even more value to our restaurant partners.'
Kraft Heinz will showcase HEINZ Verified at the National Restaurant Association Show in Chicago (May 17-20, 2025). Those attending can learn more about and sign up for HEINZ Verified, among other Away From Home innovations, while onsite.
As part of the HEINZ Verified program, Kraft Heinz will also debut a new content series called 'Daytrippin'' to be distributed on YouTube and packaged for streaming platforms. The series will follow actor, comedian and social media personality Steven He as he takes viewers on a road trip from Pittsburgh to Cleveland to Chicago, showcasing each city's local food culture and iconic dishes and the passionate people behind them.
Restaurant operators across the U.S. who are interested in getting HEINZ Verified can sign-up now at https://www.kraftheinzawayfromhome.com/getheinzverified. People can nominate their favorite restaurants that serve HEINZ for the program at https://www.heinz.com/heinzverified.
1 Dec '24 KHC Custom Condiment Survey, Dig Insight.
ABOUT THE KRAFT HEINZ COMPANY
We are driving transformation at The Kraft Heinz Company (Nasdaq: KHC), inspired by our Purpose, Let's Make Life Delicious. Consumers are at the center of everything we do. With 2024 net sales of approximately $26 billion, we are committed to growing our iconic and emerging food and beverage brands on a global scale. We leverage our scale and agility to unleash the full power of Kraft Heinz across a portfolio of eight consumer-driven product platforms. As global citizens, we're dedicated to making a sustainable, ethical impact while helping feed the world in healthy, responsible ways. Learn more about our journey by visiting www.kraftheinzcompany.com or following us on LinkedIn.
ABOUT UBER
Uber's mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 61 billion trips later, we're building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Experiential Retail Is Transforming American Malls With Pet Groomers And Doggy Daycare, IV Drips, And Specialty Grocers
Shopping centers and malls are diversifying and getting creative to maintain high foot traffic. The days of legacy tenants such as Bed Bath & Beyond, Filene's Basement, Modell's and Party City are long gone. Instead, experiential businesses have taken their place, according to a report by CoStar News. While experiential businesses have often been associated with nail and hair salons and restaurants, the type of retailers now occupying U.S. shopping centers has diversified to cover any operation that requires an in-person visit. CoStar reports those businesses now include pet groomers and doggy day care spaces, golf simulator clubs and even an IV drip center, all of which ply their trade alongside fast food and grocery stores like Jersey Mike's, Panda Express and Whole Foods. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Invest where it hurts — and help millions heal:. The growing trend in experiential retail centers around wellness, healthcare, fitness, recreational sports, pets, and kids. According to Forbes, at the start of the year, CoStar data showed successful retail centers were able to pivot to embrace new shopping trends. This meant smaller store sizes, experiential retail, and stores that catered to their geographic location, using data to inform site selection. 'There's a shift to smaller in general – smaller formats, shorter leases, more agile environments,' Melissa Gonzalez, principal at MG2, told Forbes. 'What is the point of the store? It's not about inventory now, especially as consumers are getting more and more comfortable shopping online. We're reevaluating the point of the store and how much of it needs to be about inventory per square foot versus experience per square foot." Fitness brands such as Lululemon (NASDAQ:LULU) now include fitness classes and wellness areas in their stores, Forbes reports. Outdoor shoe brand Sorel's Williamsburg, Brooklyn pop store offered customers an augmented reality experience in which they interacted with different weather conditions. Trending: Maximize saving for your retirement and cut down on taxes: . The COVID-19 pandemic turned the retail industry on its head. E-commerce shuttered conventional stores, and vacant spaces were filled with stores that fostered the new reality of the American consumer after the traumatizing effects of the pandemic — a greater focus on health and wellness and a place to get the pets homeowners had acquired during lockdown treated and then looked after when hybrid work conditions were imposed, CoStar reports. Equally, ethnic-style food markets, typified by H Mart, have emerged, catering to customers with a sense of culinary adventure who wish to branch out from the usual dishes they prepare at home. 'Coming out of COVID, the breadth and depth of — we don't even call them retailers anymore, it's really users — has expanded tremendously,' Doug Healey, Macerich (NYSE:MAC) senior executive vice president of leasing, said on a recent earnings call. 'So when we talk about leasing, there are the key legacy retailers. They'll always be a part of our shopping centers. But you're also looking at digitally native and emerging brands, international brands, food and beverage, restaurant, medical, entertainment, electric vehicles, fitness, home furnishings, groceries. So the uses that we have to choose from are really unprecedented today.'At the recent International Council of Shopping Centers conference in Las Vegas, a session called 'The Next Big Retail Categories' discussed emerging sectors in retail, all of which had an experiential element. These included second-hand thrift-like stores, capitalizing on the appeal of vintage apparel, especially to teens. 'Medtail' stores focusing on wellness and medical providers, exemplified by chains such as Restore Hyper Wellness, which offers drips delivering hydration, electrolytes, nutrients, and more. Spas such as Freeze & Float in Chicago offer customers the opportunity to experience hot and cold therapy treatments. 'Healthcare providers are seeking retail locations to improve patient accessibility, with location/ proximity being the second most important factor for patients choosing a provider,' commercial real estate brokerage Jones Lang LaSalle (NYSE:JLL) said in a recent report on medtail. 'There's a growing trend in wellness and preventative care services, especially in affluent areas, with concepts like IV drip clinics expanding into retail locations.' Read Next:Can you guess how many retire with a $5,000,000 nest egg? . Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Experiential Retail Is Transforming American Malls With Pet Groomers And Doggy Daycare, IV Drips, And Specialty Grocers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
